Abstract
Neisseria meningitidis (N. meningitidis) causes sepsis, epidemic meningitis, and sometimes also meningoencephalitis. Despite early antibiotic treatment, mortality and morbidity remain significant. We present recent studies on meningococcal disease with focus on the pathophysiology caused by bacterial virulence factors and the host immune responses. The bacterial outer membrane lipopolysaccharide and non-lipopolysaccharide components are related to meningococcal adhesion and invasion, while the host immune reactions propagate inflammation and neurodegeneration. Hence, bacterium-host interactions are key determinants of the clinical course and risk of fatal outcome. Accordingly, successful treatment of severe meningococcal disease requires not only antibiotics but also adjuvants targeting the released endotoxins and the host immune/inflammatory responses. This review highlights the most recent data and current knowledge on molecular mechanisms of meningococcal disease and explains how host immune responses ultimately may aggravate neuropathology and the clinical prognosis. Within this context, particular importance is paid to the endotoxic components that provide potential drug targets for novel neuroprotective adjuvants, which are needed in order to improve the clinical management of meningoencephalitis and patient prognosis.
Keywords: Inflammation, meningitis, infection, neuroprotection, medical treatment, N. meningitidis, nasopharynx, meningococcemia, meningococcal disease, L-glycero-D-mannoheptopyranoside, transferrin, lactoferrin, LPS, OMPs, CD66, ROS, brain parenchyma, Intraparenchymal neuropathology, encephalitis, hypertrophy, hyperplasia
CNS & Neurological Disorders - Drug Targets
Title: Meningococcal Disease and Future Drug Targets
Volume: 10 Issue: 1
Author(s): L. K. Gammelgaard, H. Colding, S. H. Hartzen and M. Penkowa
Affiliation:
Keywords: Inflammation, meningitis, infection, neuroprotection, medical treatment, N. meningitidis, nasopharynx, meningococcemia, meningococcal disease, L-glycero-D-mannoheptopyranoside, transferrin, lactoferrin, LPS, OMPs, CD66, ROS, brain parenchyma, Intraparenchymal neuropathology, encephalitis, hypertrophy, hyperplasia
Abstract: Neisseria meningitidis (N. meningitidis) causes sepsis, epidemic meningitis, and sometimes also meningoencephalitis. Despite early antibiotic treatment, mortality and morbidity remain significant. We present recent studies on meningococcal disease with focus on the pathophysiology caused by bacterial virulence factors and the host immune responses. The bacterial outer membrane lipopolysaccharide and non-lipopolysaccharide components are related to meningococcal adhesion and invasion, while the host immune reactions propagate inflammation and neurodegeneration. Hence, bacterium-host interactions are key determinants of the clinical course and risk of fatal outcome. Accordingly, successful treatment of severe meningococcal disease requires not only antibiotics but also adjuvants targeting the released endotoxins and the host immune/inflammatory responses. This review highlights the most recent data and current knowledge on molecular mechanisms of meningococcal disease and explains how host immune responses ultimately may aggravate neuropathology and the clinical prognosis. Within this context, particular importance is paid to the endotoxic components that provide potential drug targets for novel neuroprotective adjuvants, which are needed in order to improve the clinical management of meningoencephalitis and patient prognosis.
Export Options
About this article
Cite this article as:
K. Gammelgaard L., Colding H., H. Hartzen S. and Penkowa M., Meningococcal Disease and Future Drug Targets, CNS & Neurological Disorders - Drug Targets 2011; 10 (1) . https://dx.doi.org/10.2174/187152711794488584
DOI https://dx.doi.org/10.2174/187152711794488584 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dural Venous Sinuses: What We Need to Know
Current Medical Imaging Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Detection of Antibiotic Resistance Genes Among Multiple Drug Resistant Pseudomonas Aeruginosa Isolated from Clinical Sources in Selected Health Institutions in Kwara State
Infectious Disorders - Drug Targets Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Advances in Adjuvant Therapy Against Acute Bacterial Meningitis
Current Drug Targets - Infectious Disorders Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System
Current Neuropharmacology Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Enhanced Efficacy of DNA Vaccines Against an Intracellular Bacterial Pathogen by Genetic Adjuvants
Current Pharmaceutical Biotechnology Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy
Recent Patents on Anti-Infective Drug Discovery Proteomic Analysis of Differentially Expressed Proteins in <i>Mycobacterium Tuberculosis</i>-Infected Macrophages
Current Proteomics Current Status and Future of Antifungal Therapy for Systemic Mycoses
Recent Patents on Anti-Infective Drug Discovery Spatio-temporal Distribution of Meningitis in HIV Patients in Northern Egypt (2000-2018)
Current HIV Research The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design